Oncimmune (LON:ONC) Hits New 52-Week Low – Should You Sell?

Oncimmune Holdings plc (LON:ONC) shares hit a new 52-week low during trading on Thursday . The company traded as low as GBX 1.10 ($0.01) and last traded at GBX 1.15 ($0.01), with a volume of 728909 shares changing hands. The stock had previously closed at GBX 1.59 ($0.02).

Oncimmune Stock Down 27.7 %

The firm has a market capitalization of £1.30 million, a P/E ratio of 0.13 and a beta of 1.19. The company has a debt-to-equity ratio of -412.06, a current ratio of 1.14 and a quick ratio of 0.63. The stock has a fifty day moving average of GBX 8.11 and a 200 day moving average of GBX 13.48.

Oncimmune (LON:ONC) last posted its quarterly earnings data on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.